Home » Stocks » Beam Therapeutics

Beam Therapeutics Inc. (BEAM)

Stock Price: $30.47 USD 1.46 (5.03%)
Updated Jul 9, 2020 2:19 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.57B
Revenue (ttm) 24,000
Net Income (ttm) n/a
Shares Out 49.66M
EPS (ttm) -8.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $30.47
Previous Close $29.01
Change ($) 1.46
Change (%) 5.03%
Day's Open 29.20
Day's Range 28.43 - 30.47
Day's Volume 218,599
52-Week Range 13.00 - 31.80

More Stats

Market Cap 1.57B
Enterprise Value 1.31B
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.66M
Float 24.30M
EPS (basic) n/a
EPS (diluted) -8.35
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.10M
Short Ratio 4.31
Short % of Float 3.14%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 65,364.62
PB Ratio 5.79
Revenue 24,000
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 255.08M
Net Cash / Share 4.95
Gross Margin 75.00%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -29.07%
ROE -48.14%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$31.75*
(4.20% upside)
Low
31.0
Current: 30.47
High
32.0
Target: 31.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue0.02--
Gross Profit0.02--
Operating Income-75.15-45.74-7.88
Net Income-78.33-115-8.00
Shares Outstanding6.482.890.26
Earnings Per Share-14.05-40.54-37.47
Operating Cash Flow-72.00-20.30-2.71
Capital Expenditures-12.52-13.12-0.35
Free Cash Flow-84.52-33.42-3.05
Cash & Equivalents1051481.93
Total Debt10.0513.75-
Net Cash / Debt95.131341.93
Assets1561672.40
Liabilities55.1532.986.59
Book Value-201-117-9.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Beam Therapeutics Inc.
Country United States
Employees 87
CEO John Evans

Stock Information

Ticker Symbol BEAM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BEAM

Description

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.